Core Insights - The project initiated by the China Cancer Foundation and supported by Merck aims to implement a comprehensive cervical cancer prevention program in low-resource areas of China, starting in Shanxi Province [1][4] - Merck has donated a total of 81,000 doses of HPV vaccines to the China Cancer Foundation, which will be distributed for free vaccination of eligible middle school girls in various provinces [1][2] - The project is significant for reducing the burden of HPV-related diseases and is aligned with China's goal of eliminating cervical cancer as part of the Healthy China initiative [1][4] Group 1: Project Implementation - The cervical cancer prevention project officially launched on December 29, 2023, after nearly six months of preparation, including training healthcare personnel and conducting surveys [1][4] - The project specifically targets middle school girls, as vaccination at a younger age is believed to elicit a better immune response and provide more effective protection [3][4] - The initiative is part of a broader strategy to address the rising incidence of cervical cancer in China, particularly among younger women [2][3] Group 2: Public Health Context - HPV infection is a major health threat for women in China, with the country reporting the highest number of cervical cancer cases globally in 2022 [2] - The World Health Organization has emphasized the importance of HPV vaccination as a key preventive measure against cervical cancer, which is increasingly recognized as a public health issue in China [2][3] - The project aligns with the WHO's global strategy to accelerate the elimination of cervical cancer and China's own action plan for 2023-2030 [2][4]

无锡的实践更具示范意义。作为长三角地区首个开展该项目的城市，无锡自2021年12月便启动适龄女生 HPV疫苗免费接种项目，累计完成近13万剂次接种，服务适龄女生近7万人。"我们建立了专项工作领导 小组，明确教育、财政、卫生三部门职责，通过四年实践形成了成熟的工作机制，为全省推广提供了可 复制的经验。"无锡市卫生健康委基层妇幼处负责人说。 "以前总担心上班没时间带孩子接种，现在社区接种点周末也开放，还能线上预约，太方便了。"淮安市 清江浦区市中社区卫生服务中心接种点，陪女儿完成接种的家长王女士对便民服务赞不绝口。为破 解"上班没空、下班没号"的难题，江苏各地按照省卫健委"开设周末接种专场或延长工作日时间"的指导 要求，推出多项便民举措，让疫苗接种既有"温度"又有效率。 12月的一个周末，宿迁市沭阳县妇幼保健院疫苗接种大厅，沭阳县梦溪中学初二年级100名女生集体接 种第二剂次国产双价HPV疫苗。"我今年5月份接种了第一针，今天来接种第二针。"现场接种疫苗的女 生小刘说。记者从江苏省卫生健康委获悉，为在校适龄女生免费接种HPV疫苗已连续三年被纳入省政府 民生实事项目。最新数据显示，今年前10个月，全省已为19.7万 ...

Core Insights - The first domestic nine-valent HPV vaccine was officially administered in Beijing on December 4, marking a significant step in cervical cancer prevention efforts in China [1] - Despite the approval of multiple HPV vaccines, the overall vaccination rate in China remains below the global average, indicating challenges in public awareness and accessibility [2][10] Industry Overview - China has the largest variety of HPV vaccines globally, with two domestic bivalent vaccines having received WHO pre-qualification, ensuring their safety and efficacy [2][3] - The vaccination coverage rates for HPV among women aged 9-45 in mainland China were reported at 10.15% for the first dose and 6.21% for the full series in 2022, with only 4.00% for girls aged 9-14 [3] Public Health Goals - The WHO's 2020 strategy aims for 90% of girls to complete HPV vaccination by age 15 by 2030, with a target incidence rate of cervical cancer below 4 cases per 100,000 women [4][7] - Countries with high vaccination coverage, such as Australia and Finland, have seen cervical cancer rates drop significantly, demonstrating the effectiveness of vaccination and screening programs [7] Challenges and Opportunities - Public awareness and willingness to vaccinate remain low, with factors such as pricing and lack of information contributing to the hesitance [10][11] - The inclusion of HPV vaccines in the national immunization program aims to provide free vaccinations for eligible girls, potentially increasing uptake [8] Recommendations for Improvement - Enhanced public education initiatives are necessary to inform parents about the importance of HPV vaccination, particularly targeting the appropriate age for administration [10][11] - A comprehensive management system integrating health consultation, vaccination, screening, and treatment is recommended to improve overall cervical cancer prevention efforts [11]

Core Points - The World Health Organization (WHO) congratulated China for its milestone decision to include the HPV vaccine in the national immunization program, marking a significant advancement in cervical cancer prevention and women's health [1][2] - Starting from November 10, 2025, China will provide free vaccinations for two doses of the bivalent HPV vaccine to girls born on or after November 10, 2011, who are 13 years old and above [1] - The initiative is expected to significantly contribute to the global effort to eliminate cervical cancer, with WHO emphasizing the importance of early vaccination for optimal protection and cost-effectiveness [1][2] Summary by Sections HPV Vaccination Program - The free HPV vaccination program will target girls aged 13 and above, laying a solid foundation for expanding protection to more adolescents in the future [2] - This initiative reflects China's commitment to the "Healthy China 2030" plan and the "Accelerated Action to Eliminate Cervical Cancer" plan for 2023-2030 [2] Global Health Impact - WHO's global strategy aims for 90% of girls to complete HPV vaccination by age 15, 70% of women to be screened, and 90% of diagnosed cervical cancer patients to receive treatment by 2030 [2] - China's leadership in implementing the HPV vaccination program sets a benchmark for the region and globally [2] Collaboration and Support - WHO is collaborating closely with Chinese authorities to support the effective implementation of the HPV vaccination program through education, training, and evaluation [2] - The initiative demonstrates the potential for remarkable outcomes when science, political will, and public health efforts align [2]

Group 1: HPV Vaccine Inclusion in National Immunization Program - The Chinese government has decided to include the HPV vaccine in the national immunization program starting from November 10, 2025, allowing eligible girls to receive the vaccine for free [1][2] - This initiative is a significant step towards China's commitment to eliminate cervical cancer by 2030, as outlined in the global strategy by the World Health Organization [1][3] Group 2: Target Population and Vaccination Details - Girls born after November 10, 2011, who are at least 13 years old will be eligible for two doses of the bivalent HPV vaccine, with a six-month interval between doses [2] - Local health authorities are required to assess the number of eligible girls and their previous vaccination status, and to set up vaccination units accordingly [6] Group 3: Market Dynamics and Production - The centralized procurement project for the bivalent HPV vaccine has a budget of approximately 425 million yuan, with a total quantity of 15.4465 million doses [8] - Only two companies are specified to produce the bivalent HPV vaccine for the national immunization program, with six HPV vaccines currently available in China, including three bivalent vaccines [10] - Domestic companies, such as Wantai Biological Pharmacy and Watson Biotech, have successfully launched their bivalent HPV vaccines, contributing to a more competitive market landscape [10][11] Group 4: Competitive Landscape - The domestic HPV vaccine market is becoming increasingly diversified, with imported products like Merck's nine-valent HPV vaccine and four-valent HPV vaccine leading the high-priced segment [11] - New entrants, such as China National Pharmaceutical Group's four-valent HPV vaccine, have recently received approval, indicating a shift in market dynamics [11]

Core Viewpoint - The introduction of the first domestic nine-valent HPV vaccine and its expanded vaccination range marks a significant step towards increasing accessibility and affordability of HPV vaccines in China, potentially leading to a "cervical cancer elimination" strategy [3][5]. Group 1: HPV Vaccine Market Overview - Currently, there are six approved HPV vaccines in China, with three being imported and three domestic. The market has been dominated by imported products, particularly Merck's and GSK's vaccines, which accounted for over 90% of the market share [3]. - The entry of domestic vaccines, such as those from Wantai Biological Pharmacy, has led to a decrease in prices and improved accessibility for the population [3]. Group 2: National Immunization Planning - The recent announcement by the State Council to include HPV vaccines in the national immunization program is expected to enhance vaccination rates, as evidenced by international examples where such programs have been implemented [3][4]. - As of now, specific implementation details regarding the national immunization plan for HPV vaccines have not been disclosed, but experts anticipate a phased approach prioritizing key demographics [5]. Group 3: Target Demographics and Public Health Strategy - University students are identified as a key demographic for HPV prevention, as proactive measures during this stage can yield high health investment returns [5]. - The importance of "gender-neutral vaccination" is emphasized, as studies indicate that widespread vaccination can significantly reduce cervical cancer cases and provide indirect protection to partners through herd immunity [6].

Core Insights - The first domestically produced nine-valent HPV vaccine has opened for appointments and is being administered nationwide, with the vaccination range expanded to ages 9 to 17 [1] - Currently, there are six approved HPV vaccines in China, with three being imported and three domestically produced, previously dominated by imported products [1] - The inclusion of HPV vaccines in the national immunization program is expected to enhance accessibility and contribute to the goal of "eliminating cervical cancer" [1][2] Group 1 - The domestic HPV vaccine market is seeing increased competition, leading to a decrease in prices and improved accessibility for the population [1] - As of now, 149 countries have included HPV vaccines in their national immunization programs, with an average vaccination rate of about 60% [1] - Countries like Canada, Australia, and the UK have achieved high vaccination rates of 86%, 71%, and 68% respectively in 2023 [1] Group 2 - Australia's multi-tiered service system for HPV vaccination includes school-based programs and community clinics, which could serve as a model for China's implementation [2] - Experts predict that the rollout of free HPV vaccines in China will be phased, initially targeting key populations before expanding to a broader audience [2] - The focus on university students as a key demographic for HPV prevention is based on public health strategies, emphasizing the high return on investment for health measures during this stage [2] Group 3 - The concept of "gender-neutral vaccination" is gaining traction, with studies indicating that widespread vaccination can significantly reduce cervical cancer cases by 90% [3] - Vaccination of both males and females can establish strong herd immunity, reducing the transmission of HPV and protecting the entire population [3] - The latest guidelines advocate for the importance of HPV vaccination for both genders, highlighting the broader health benefits of such an approach [3]

Core Viewpoint - The introduction of the domestically produced nine-valent HPV vaccine in Guangdong marks a significant advancement in cervical cancer prevention, providing new options for women aged 9 to 45 and expected to increase vaccination rates among younger girls due to policy support [1][3][10]. Summary by Sections Vaccine Introduction and Coverage - The first batch of the domestically produced nine-valent HPV vaccine was successfully administered in Guangdong on October 16, 2023, making it the first of its kind in the province [1]. - The vaccine is approved for women aged 9 to 45, with a two-dose regimen for those aged 9 to 17 and a three-dose regimen for those aged 18 to 45, priced at 1040 yuan and 1560 yuan respectively [3][10]. Cervical Cancer Statistics - Cervical cancer remains a major health threat for women in China, with 151,000 new cases and 56,000 deaths reported in 2022, indicating a rising incidence among younger women [6][10]. - HPV is responsible for 99.7% of cervical cancer cases, with high-risk types being the primary concern [6][7]. Vaccine Efficacy and Public Response - Clinical trials show that the vaccine provides 100% protection against persistent infections from seven high-risk HPV types over a 32-month observation period [3][6]. - There is a growing interest in the vaccine, with many women actively seeking appointments for vaccination, indicating a positive public response [9][10]. Accessibility and Affordability - The introduction of the vaccine at a subsidized price marks the beginning of a "universal access" era for HPV vaccination, addressing key public health challenges of accessibility, sustainability, and affordability [10]. - The vaccination rates among women aged 9 to 45 have increased from 0.01% to 10.15% for the first dose and from 0% to 6.21% for the three-dose regimen between 2017 and 2022 [10]. Recommendations for Prevention - Experts emphasize that vaccination should be combined with regular cervical cancer screenings to effectively prevent the disease, as the vaccine does not treat existing infections [10].

Core Viewpoint - The approval and launch of the first domestically produced nine-valent HPV vaccine in China marks a significant advancement in the country's ability to independently supply high-quality HPV vaccines, positioning China as the second country globally to achieve this capability [1][2]. Group 1: Vaccine Development and Market Impact - The nine-valent HPV vaccine, developed by a team from Xiamen University and Wantai Biological Pharmacy, is the first of its kind in China and the second globally to be approved for market use, indicating a new era of accessible cervical cancer prevention in China [2][4]. - Wantai Biological, as a leading domestic HPV vaccine manufacturer, has produced over 100 million doses of the vaccine, ensuring stable production processes and high-quality standards [4][6]. - The domestic vaccine is priced at 499 yuan per dose, approximately 40% of the cost of imported alternatives, significantly lowering the economic barrier for eligible women and expected to increase vaccination rates [6][10]. Group 2: Clinical Efficacy and Safety - The vaccine targets seven high-risk HPV types responsible for 95.4% of cervical cancer cases in China, with clinical trials involving over 10,000 women aged 9-45, demonstrating its effectiveness and safety [7][9]. - The phase III clinical trial results show a 100% protection rate against persistent infections from high-risk HPV types after 12 months, highlighting its strong preventive potential [7][9]. Group 3: Public Health Policy and Implementation - The nationwide rollout of the vaccine aligns with government public health policies, including the integration of HPV vaccination into the national immunization program, which aims to enhance cervical cancer prevention efforts [10][11]. - Local initiatives, such as the free vaccination program for eligible girls in Xiamen, exemplify effective collaboration between national policies and local practices, providing a model for other regions [10][12]. - The successful introduction of the vaccine is expected to significantly improve vaccination coverage among eligible populations, contributing to the goal of eliminating cervical cancer in China [12].

Core Viewpoint - The approval and launch of the first domestically produced nine-valent HPV vaccine in China marks a significant advancement in cervical cancer prevention, providing broader access and affordability for women aged 9 to 45, and reshaping public health, economic, and social equity dimensions [1][4][12]. Market Supply and Accessibility - The domestic nine-valent HPV vaccine, developed by Xiamen University and Wantai Biological Pharmacy, has produced over 100 million doses, ensuring stable production and high-quality standards [3][4]. - The vaccine is priced at 499 yuan per dose, approximately 40% of the cost of imported alternatives, significantly lowering the economic barrier for vaccination [6][12]. - The vaccination program for women aged 9-17 requires two doses at a total cost of 998 yuan, while women aged 18-45 will need three doses costing around 1500 yuan, compared to nearly 4000 yuan for imported vaccines [6][12]. Efficacy and Safety - The vaccine targets seven high-risk HPV types responsible for 95.4% of cervical cancer cases in China, with clinical trials involving over 10,000 women aged 9 to 45, demonstrating a 100% protection rate against persistent infections after 12 months [7][9]. - The vaccine's immunogenicity and safety profile are comparable to imported products, with a 100% seroconversion rate for all HPV types [9]. Policy Support and Public Health Initiatives - The national vaccination initiative aligns with the government's public health policies, with the HPV vaccine included in the national immunization program, providing robust policy support for cervical cancer prevention [10][11]. - Local governments, such as Xiamen, have initiated programs offering free or subsidized vaccinations for eligible girls, creating a model for nationwide implementation [11][12]. Broader Implications - The successful rollout of the domestic nine-valent HPV vaccine is expected to significantly increase vaccination coverage among eligible populations, contributing to the goal of cervical cancer elimination in China [12][13]. - This development reflects the innovation capabilities of China's biopharmaceutical industry and supports the broader public health strategy of achieving universal health coverage [13].